<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623621</url>
  </required_header>
  <id_info>
    <org_study_id>CIRCUS</org_study_id>
    <nct_id>NCT02623621</nct_id>
  </id_info>
  <brief_title>Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer</brief_title>
  <acronym>CIRCUS</acronym>
  <official_title>A Single-arm Phase II Study of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) as Predictor of Benefit From Bevacizumab (Bev) Beyond Progression in Metastatic Colorectal Cancer (mCRC) - the CIRCUS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A growing amount of reports has consistently evidenced that a sustained inhibition of the&#xD;
      angiogenesis is an effective therapeutic strategy, able to improve the outcome of metastatic&#xD;
      colorectal cancer (mCRC) patients.&#xD;
&#xD;
      In the last decade different biologic agents targeting angiogenesis have been approved for&#xD;
      the treatment of mCRC, such as bevacizumab, aflibercept and regorafenib, and, more recently,&#xD;
      solid evidences have demonstrated the efficacy of a sustained antiangiogenic approach even&#xD;
      beyond the first progression to a bevacizumab-containing regimen. In particular, two phase&#xD;
      III randomized trials proved the effectiveness of prosecuting bevacizumab in second-line&#xD;
      switching the chemotherapeutic regimen in patients already treated with bevacizumab in&#xD;
      first-line. Preliminary experiences evidenced that circulating levels of angiogenesis-related&#xD;
      markers are significantly modulated during first-line chemotherapy plus bevacizumab. In&#xD;
      particular, a wide variability of plasma soluble Vascular Endothelial Growth Factor&#xD;
      Receptor-2 (VEGFR-2) levels is observed at the time of disease progression and retrospective&#xD;
      data suggest that benefit from the continuation of bevacizumab may be restricted to patients&#xD;
      with high levels of soluble VEGFR-2 at the first evidence of disease progression. This study&#xD;
      aims at prospectively validating those retrospective data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>from treatment start until disease progression, according to RECIST 1.1, or death due to any cause, whichever occurs first, up to 12 months after last patient last visit</time_frame>
  </primary_outcome>
  <enrollment type="Actual">103</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy plus bevacizumab</intervention_name>
    <description>Every chemotherapy regimen combined with bevacizumab is allowed</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Paired plasma and blood samples will be collected at baseline, at the time of every disease&#xD;
      assessment and at the time of disease progression&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mCRC progressed on or after a 1st-line bevacizumab-containing regimen and&#xD;
        candidate to continue bevacizumab beyond progression, in combination with a 2nd-line&#xD;
        chemotherapy regimen.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of â‰¥ 18 years of age&#xD;
&#xD;
          -  Progressive disease during or after first-line chemotherapy plus bevacizumab,&#xD;
             including fluoropyrimidine alone (5-fluorouracil or capecitabine), fluoropyrimidine in&#xD;
             combination with oxaliplatin (XELOX or FOLFOX regimen) or irinotecan (FOLFIRI regimen)&#xD;
             or with oxaliplatin and irinotecan (FOLFOXIRI regimen);&#xD;
&#xD;
          -  No more than 3 months from the last administration of bevacizumab and evidence of&#xD;
             progressive disease are allowed;&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1.&#xD;
&#xD;
          -  Indication to second-line treatment with a bevacizumab-containing second-line regimen&#xD;
             (second-line XELOX, FOLFOX, FOLFIRI and FOLFOXIRI plus bevacizumab are allowed);&#xD;
&#xD;
          -  Neutrophils 1.5 x 109/L, Platelets 100 x 109/L, Hgb &gt;9 g/dl&#xD;
&#xD;
          -  Total bilirubin 1.5 time the upper-normal limits (UNL) of the institutional normal&#xD;
             values and ASAT (SGOT) and/or ALAT (SGPT) 2.5 x UNL, or 5 x UNL in case of liver&#xD;
             metastases, alkaline phosphatase 2.5 x UNL, 5 x UNL in case of liver metastases&#xD;
&#xD;
          -  Creatinine clearance &gt;50 mL/min or serum creatinine 1.5 x UNL&#xD;
&#xD;
          -  Urine dipstick of proteinuria &lt;2+. Patients discovered to have 2+ proteinuria on&#xD;
             dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must&#xD;
             demonstrate &lt;1 g of protein/24 hr&#xD;
&#xD;
          -  Will and ability to comply with the protocol&#xD;
&#xD;
          -  Written informed consent to study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to give consent&#xD;
&#xD;
          -  Absolute contraindications to the use of bevacizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Alfredo Falcone</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

